Convalescent plasma for pediatric patients with COVID-19 associated acute respiratory distress syndrome

Caroline Diorio,Elizabeth Anderson,Kevin McNerney,Eileen Goodwin,Julie Chase,Marcus Bolton,Claudia Arevalo,Madison Weirick,Sigrid Gouma,Laura Vella,Sarah Henrickson,Kathleen Chiotos,Julie Fitzgerald,Todd Kilbaugh,Audrey Odom John,Allison Blatz,Michele Lambert,Kathleen Sullivan, Margaret Tartaglione, Danielle Zambrano, Meghan Martin,Jessica Lee,Pampee Young,David Friedman, Deborah Sesok Pizzini,Scott Hensley,Edward Behrens,Hamid Bassiri,David Teachey

Authorea (Authorea)（2020）

引用 0|浏览0

暂无评分

摘要

There are no proven safe and effective therapies for children who develop life-threatening complications of SARS-CoV-2. Convalescent plasma (CP) has demonstrated potential benefit in adults with SARS-CoV-2 but has theoretical risks. We report on the first use of CP in children with life-threatening COVID-19, providing data on four pediatric patients with acute respiratory distress syndrome. We measured donor antibody levels and recipient antibody response prior to and following CP infusion. Infusion of CP was not associated with antibody-dependent enhancement (ADE) and did not suppress endogenous antibody response. We found CP was safe and possibly efficacious. Randomized pediatric trials are needed.

查看译文

关键词

acute respiratory distress syndrome,pediatric patients,plasma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要